Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisonorm is a fixed-dose combination (FDC) medication containing lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and amlodipine, a dihydropyridine calcium channel blocker. It is primarily indicated for the treatment of primary hypertension in patients whose blood pressure is not adequately controlled by monotherapy. Lisinopril works by inhibiting the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, thereby reducing peripheral vascular resistance and aldosterone secretion. Amlodipine acts by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased blood pressure. The combination provides a synergistic effect, improving efficacy and potentially reducing the incidence of side effects like peripheral edema associated with amlodipine. Sichuan Shangrui Biopharmaceutical has developed a generic version of this product, which was originally marketed by Gedeon Richter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lisinopril + amlodipine.